Teva says oral MS drug laquinimod may reduce brain tissue damage
TEL AVIV (Reuters) - Israel's Teva Pharmaceutical Industries and Sweden's Active Biotech said a Phase III clinical trial of laquinimod, an oral treatm...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/T8ihxqvlrMY/story01.htm
No comments:
Post a Comment